Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

The Cambridge, Massachusetts-based company said it had profit of 3 cents per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...

Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older, ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive officer of the biotech company.

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost significantly in the past couple of years due to declining sales amid low demand ...

Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...

18 analysts have expressed a variety of opinions on Moderna (NASDAQ:MRNA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...